https://mds-hub.com daily 1 2026-04-03T18:49:35.978Z https://mds-hub.com/types weekly 0.8 2024-11-12T12:33:00.000Z https://mds-hub.com/types/myelodysplasticmyeloproliferative-neoplasms weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/therapy-related-myeloid-neoplasms weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/mds-related-mutations weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/risk weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/disease weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/mds-precursor-conditions weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/myelodysplastic-syndromes weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/types/elderly-patients weekly 0.7 2024-12-04T17:40:00.000Z https://mds-hub.com/therapeutics weekly 0.8 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/hypomethylating-agents weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/bcl-2-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/tgf-b-pathway-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/axl weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/idh1-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/immune-modulators weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/tocilizumab weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/vibecotamab weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/antibody-therapy weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/erythropoiesis-stimulating-agents weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/cytokine-receptor-agonists weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/telomerase-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/kinase-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/enzyme-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/conjugated-antibodies weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/iron-chelators-1 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/idh2-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/cellular-therapy weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/chemotherapy weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/prolyl-hydroxylase-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/car-t-cell-therapy weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/checkpoint-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/tp53-activators weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/microbiota-therapy weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/therapeutics/mdm2-inhibitors weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials weekly 0.8 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/commands weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/stimulus-mds1 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/stimulus-mds2 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/medalist weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/promys weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/bergamo weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/bmt-ctn-1102 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/reset-02 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/fisim-luspa weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/agile weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/tocilam weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/eqol-mds weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/imerge weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/takeaim-leukemia weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/p-2001 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/the-national-mds-natural-history-study weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/aml18 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/eumds weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/ascertain weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/nct03268954 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/azalena weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/ideal weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/nct03263091 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/nct04733729 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/sintra-rev weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/dacota weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/cimon weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/astx727-01 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/ksgct1702-ctdna weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/gfm-apr weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/trials/5f9005 weekly 0.7 2024-11-12T12:33:00.000Z https://mds-hub.com/expert-opinions weekly 0.8 2025-02-07T16:52:00.000Z https://mds-hub.com/drug-updates weekly 0.8 2025-02-07T16:52:00.000Z https://mds-hub.com/medical-information/editorial-theme-understanding-the-new-classification-and-stratification-systems-in-mds-ipss-r-and-ipss-m monthly 0.9 2023-12-22T13:55:00.000Z https://mds-hub.com/medical-information/how-i-treat-based-on-the-newupdated-classification-systems monthly 0.9 2023-12-14T11:37:00.000Z https://mds-hub.com/medical-information/how-i-treat-a-patient-with-lower-risk-mds-showing-signs-of-esa-failure monthly 0.9 2023-12-12T16:40:00.000Z https://mds-hub.com/medical-information/expert-recommendations-for-clinical-trial-design-to-facilitate-drug-development-in-mds monthly 0.9 2024-01-16T12:39:00.000Z https://mds-hub.com/medical-information/the-long-term-benefit-of-luspatercept-analysis-from-the-phase-iii-medalist-trial monthly 0.9 2023-12-08T15:14:00.000Z https://mds-hub.com/medical-information/health-related-quality-of-life-profile-of-newly-diagnosed-patients-with-mds-a-real-world-study monthly 0.9 2023-11-29T15:25:00.000Z https://mds-hub.com/medical-information/bemcentinib-in-patients-with-hr-mds-or-aml-who-are-rr-to-hmas-results-from-the-phase-ii-bergamo-trial monthly 0.9 2023-11-08T15:49:00.000Z https://mds-hub.com/medical-information/editorial-theme-understanding-mds-classification-and-stratification-systems-who-and-icc monthly 0.9 2023-11-08T10:58:00.000Z https://mds-hub.com/medical-information/allo-hsct-in-patients-with-high-risk-mds-analysis-from-the-bmt-ctn-1102-trial monthly 0.9 2023-11-07T11:23:00.000Z https://mds-hub.com/medical-information/mdsmpn-diagnostic-differences-between-who-5th-edition-and-icc-schemes monthly 0.9 2023-11-01T12:01:00.000Z https://mds-hub.com/medical-information/ivosidenib-granted-fda-approval-for-the-treatment-of-patients-with-rr-idh1-mutated-mds monthly 0.9 2023-10-25T15:58:00.000Z https://mds-hub.com/medical-information/what-do-data-from-the-phase-iii-commands-trial-reveal-about-luspatercept-as-a-treatment-option monthly 0.9 2023-10-20T08:25:00.000Z https://mds-hub.com/medical-information/visual-abstract-or-priority-agenda-to-advance-research-in-mds-the-first-international-workshop-in-mds monthly 0.9 2023-10-13T09:54:00.000Z https://mds-hub.com/medical-information/initiation-of-the-phase-iii-reset-02-trial-of-smart101-for-the-treatment-of-aml monthly 0.9 2023-09-29T08:58:00.000Z https://mds-hub.com/medical-information/referral-patterns-and-potential-barriers-to-transplantation-in-patients-with-mds monthly 0.9 2023-09-13T12:50:00.000Z https://mds-hub.com/medical-information/the-impact-of-post-transplant-mrd-on-survival-in-aml-and-mds-an-analysis-from-the-phase-ii-figaro-trial monthly 0.9 2023-09-12T14:02:00.000Z https://mds-hub.com/medical-information/real-world-treatment-patterns-and-outcomes-with-luspatercept-in-patients-with-lower-risk-myelodysplastic-syndrome monthly 0.9 2023-09-07T14:18:00.000Z https://mds-hub.com/medical-information/impact-of-lenalidomide-discontinuation-in-patients-with-mds-and-del-5q-achieving-transfusion-independence-harmony-alliance-study monthly 0.9 2023-08-31T14:39:00.000Z https://mds-hub.com/medical-information/luspatercept-granted-fda-approval-as-a-first-line-treatment-for-anemia-in-patients-with-lower-risk-mds monthly 0.9 2023-08-29T15:20:00.000Z https://mds-hub.com/medical-information/fda-grants-priority-review-and-accepts-supplemental-new-drug-application-for-oral-ivosidenib-for-the-treatment-of-patients-with-idh1-mutated-rr-mds monthly 0.9 2023-08-17T10:10:00.000Z https://mds-hub.com/medical-information/updates-from-asco-and-eha-on-the-efficacy-and-safety-of-ivosidenib-including-molecular-characterization-and-long-term-follow-up-in-patients-with-mutant-idh1-aml-and-rr-mds monthly 0.9 2023-08-15T10:13:00.000Z https://mds-hub.com/medical-information/an-overview-of-developments-in-immune-based-therapies-in-the-treatment-of-aml-and-mds-updates-from-asco23 monthly 0.9 2023-08-07T12:01:00.000Z https://mds-hub.com/medical-information/luspatercept-for-esa-naive-td-patients-with-lr-mds-interim-analysis-from-the-commands-study monthly 0.9 2023-07-27T10:01:00.000Z https://mds-hub.com/medical-information/eltrombopag-for-patients-with-lr-mds-and-thrombocytopenia-results-from-the-eqol-mds-trial monthly 0.9 2023-07-13T09:48:00.000Z https://mds-hub.com/medical-information/imetelstat-in-patients-with-lower-risk-mds-updates-from-the-imerge-trial monthly 0.9 2023-07-06T09:03:00.000Z https://mds-hub.com/medical-information/fda-lifts-partial-clinical-hold-on-phase-iii-takeaim-leukemia-trial-of-emavusertib-in-patients-with-aml-and-mds monthly 0.9 2023-07-07T15:59:00.000Z https://mds-hub.com/medical-information/american-society-for-transplantation-and-cellular-therapy-recommendations-for-allo-hsct-in-mds monthly 0.9 2023-06-28T10:15:00.000Z https://mds-hub.com/medical-information/cpx-351-versus-flag-ida-in-patients-with-adverse-karyotype-aml-and-high-risk-mds-analysis-from-ncri-aml19-trial monthly 0.9 2023-06-20T11:00:00.000Z https://mds-hub.com/medical-information/quality-of-life-assessment-and-transfusion-free-survival monthly 0.9 2023-06-29T09:07:00.000Z https://mds-hub.com/medical-information/hrqol-and-vulnerability-analysis-from-the-national-mds-natural-history-study monthly 0.9 2023-06-28T09:38:00.000Z https://mds-hub.com/medical-information/patients-perspectives-on-the-use-of-oral-decitabine-and-cedazuridine-in-the-treatment-of-mds monthly 0.9 2023-06-22T14:14:00.000Z https://mds-hub.com/medical-information/eha2023-abstracts-what-s-hot-in-mds monthly 0.9 2023-06-06T09:23:00.000Z https://mds-hub.com/medical-information/how-can-structural-variant-assessment-assist-in-mrd-assessment-in-mds monthly 0.9 2023-05-10T13:34:00.000Z https://mds-hub.com/medical-information/the-utility-of-targeted-exon-sequencing-in-the-diagnosis-of-mds-in-people-with-cytopenia monthly 0.9 2023-04-24T12:26:00.000Z https://mds-hub.com/medical-information/luspatercept-granted-priority-review-by-the-fda-and-type-ii-variation-application-validated-by-the-ema-for-first-line-treatment-of-anemia-in-lower-risk-mds monthly 0.9 2023-05-02T14:29:00.000Z https://mds-hub.com/medical-information/how-i-treat-case-studies-incorporating-updated-classification-systems monthly 0.9 2023-04-18T10:00:00.000Z https://mds-hub.com/medical-information/magrolimab-plus-azacitidine-in-patients-with-higher-risk-mds-updated-results-from-a-phase-ib-study-5f9005 monthly 0.9 2023-04-21T08:40:00.000Z https://mds-hub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-19T10:20:00.000Z https://mds-hub.com/medical-information/revised-international-working-group-2023-response-criteria-for-higher-risk-mds monthly 0.9 2023-04-05T13:38:00.000Z https://mds-hub.com/medical-information/omidubicel-onlv-granted-fda-approval-for-patients-with-hematologic-malignancies-eligible-for-umbilical-cord-blood-transplantation monthly 0.9 2023-04-19T10:48:00.000Z https://mds-hub.com/medical-information/visual-abstract-or-key-updates-to-the-classification-of-mds-in-the-5th-who-classification-of-haematolymphoid-tumours monthly 0.9 2023-03-27T11:30:00.000Z https://mds-hub.com/medical-information/common-genomic-diagnostic-tests monthly 0.9 2023-03-24T12:27:00.000Z https://mds-hub.com/medical-information/international-consensus-classification-of-mds-2022-updates monthly 0.9 2023-03-15T12:02:00.000Z https://mds-hub.com/medical-information/addition-of-gemtuzumab-ozogamicin-to-induction-chemotherapy monthly 0.9 2023-03-29T14:10:00.000Z https://mds-hub.com/medical-information/health-related-quality-of-life-in-patients-with-mds monthly 0.9 2023-02-24T12:07:00.000Z https://mds-hub.com/medical-information/novel-treatment-strategies-in-patients-with-high-risk-and-low-risk-mds monthly 0.9 2023-02-21T09:58:00.000Z https://mds-hub.com/medical-information/real-world-validation-of-the-ipss-m-risk-stratification-model-for-mds-and-comparison-to-ipss-r monthly 0.9 2023-02-07T11:16:00.000Z https://mds-hub.com/medical-information/is-there-confusion-between-who-and-ipss-m-classifications-of-mds monthly 0.9 2023-01-30T10:00:00.000Z https://mds-hub.com/medical-information/tamibarotene-granted-fast-track-designation-by-the-fda monthly 0.9 2023-01-27T16:29:00.000Z https://mds-hub.com/medical-information/latest-insights-on-tp53-mutations-in-aml-and-mds-from-ash-2022 monthly 0.9 2023-01-23T13:31:00.000Z https://mds-hub.com/medical-information/challenges-of-measuring-overall-survival-in-elderly-patients-with-mds monthly 0.9 2023-01-10T13:57:00.000Z https://mds-hub.com/medical-information/briquilimab-granted-orphan-drug-designation-by-the-european-commission monthly 0.9 2023-01-05T16:37:00.000Z https://mds-hub.com/medical-information/association-between-prior-lenalidomide-exposure-and-tp53-mutated-therapy-related-mds monthly 0.9 2022-12-13T15:33:00.000Z https://mds-hub.com/medical-information/ash-2022 monthly 0.9 2022-12-07T11:17:00.000Z https://mds-hub.com/medical-information/ash-2022-top-abstracts-in-myelodysplastic-syndromes monthly 0.9 2023-02-09T12:03:00.000Z https://mds-hub.com/medical-information/monitoring-iron-overload-disorder-in-mds monthly 0.9 2022-11-17T12:41:00.000Z https://mds-hub.com/medical-information/visual-abstract-phase-iii-panther-trial-evaluating-pevonedistat-azacitidine-vs-azacitidine-alone-in-patients-with-higher-risk-mds-or-low-blast-percentage-aml monthly 0.9 2022-11-09T11:24:00.000Z https://mds-hub.com/medical-information/anemia-treatment-with-luspatercept-in-patients-with-lower-risk-mds-results-from-the-pace-mds-study monthly 0.9 2022-10-12T15:01:00.000Z https://mds-hub.com/medical-information/visual-abstract-or-enasidenib-as-monotherapy-and-in-combination-with-azacitidine-for-patients-with-idh2-mutated-mds-results-from-a-phase-ii-study monthly 0.9 2022-10-28T16:05:00.000Z https://mds-hub.com/medical-information/guidelines-for-allo-hsct-in-the-treatment-of-pediatric-aml-and-mds monthly 0.9 2022-10-05T15:16:00.000Z https://mds-hub.com/medical-information/real-world-transfusion-practices-and-experiences-for-patients-diagnosed-with-mds monthly 0.9 2022-09-22T11:29:00.000Z https://mds-hub.com/medical-information/editorial-theme-or-supportive-care-for-mds monthly 0.9 2022-10-12T14:35:00.000Z https://mds-hub.com/medical-information/how-do-we-differentiate-high-risk-mds-from-aml monthly 0.9 2022-08-05T13:44:00.000Z https://mds-hub.com/medical-information/aspacytarabine-granted-orphan-drug-designation-by-the-fda monthly 0.9 2022-08-05T14:03:00.000Z https://mds-hub.com/medical-information/eltanexor-granted-fast-track-designation-by-the-fda-and-orphan-medicinal-product-designation-by-the-ec monthly 0.9 2022-08-04T08:35:00.000Z https://mds-hub.com/medical-information/clofarabine-with-fludarabine-and-busulfan-in-pretransplant-conditioning-regimen-for-amlmds-results-from-a-phase-iii-study monthly 0.9 2022-08-02T12:06:00.000Z https://mds-hub.com/medical-information/how-do-we-treat-high-risk-patients-outside-of-a-clinical-trial monthly 0.9 2022-07-18T08:11:00.000Z https://mds-hub.com/medical-information/what-patient-factors-should-we-consider-for-intermediate-and-high-risk-patients-beyond-the-ipss-r-score monthly 0.9 2022-07-18T08:11:00.000Z https://mds-hub.com/medical-information/how-could-venetoclax-combinations-improve-outcome-in-high-risk-mds monthly 0.9 2022-07-11T10:26:00.000Z https://mds-hub.com/medical-information/sequence-of-therapy-in-myelodysplastic-syndromes monthly 0.9 2022-07-11T09:40:00.000Z https://mds-hub.com/medical-information/new-ipss-molecular-model-for-mds-risk-stratification-and-prognosis monthly 0.9 2022-07-12T11:43:00.000Z https://mds-hub.com/medical-information/highlights-of-the-8th-translational-research-conference-myelodysplastic-syndromes monthly 0.9 2022-07-11T09:01:00.000Z https://mds-hub.com/medical-information/hot-topics-relevant-to-mds monthly 0.9 2022-07-05T13:19:00.000Z https://mds-hub.com/medical-information/comparison-of-clinical-and-genetic-features-of-ccus-and-lower-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/editorial-theme-clinical-prognosis-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/eha2022-abstracts-what-s-hot-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/peri-transfusion-quality-of-life-assessment-to-help-future-transfusion-decisions-for-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/editorial-theme-or-molecular-diagnosis-and-prognosis-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-does-the-figaro-trial-reveal-about-predictors-of-outcome-post-transplant monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/post-hoc-analysis-of-combination-therapies-treosulfan-and-fludarabine-and-busulfan-and-fludarabine-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/conditioning-regimens-prior-to-allo-hsct-updates-from-the-48th-annual-meeting-of-the-ebmt-2022 monthly 0.9 2022-05-03T09:37:00.000Z https://mds-hub.com/medical-information/can-ipss-r-be-used-as-a-prognostic-tool-in-hsct-in-regions-where-molecular-analysis-is-unavailable monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/do-mrna-based-covid-vaccines-lead-to-adverse-events-in-recently-transplanted-patients monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/new-clinical-advances-in-mds-risk-categorization monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/factors-predisposing-failure-to-reach-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-myelodysplastic-syndromes monthly 0.9 2022-03-24T15:52:00.000Z https://mds-hub.com/medical-information/healthcare-inequalities-in-bone-marrow-transplants monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/molecular-analysis-of-tp53-mutant-aml-and-mds-eb monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/luspatercept-reduces-red-blood-cell-transfusion-burden-on-patients-with-very-low-to-intermediate-risk-mds-without-negative-impact-on-health-related-quality-of-life monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/editorial-theme-or-impact-of-using-a-fixed-blast-percentage-threshold-on-aml-and-mds-treatment-options monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/visual-abstract-lenalidomide-and-eltrombopag-for-treatment-in-low-or-intermediate-risk-myelodysplastic-syndrome-result-of-a-phase-2-study-combination-clinical-trial monthly 0.9 2022-10-28T16:05:00.000Z https://mds-hub.com/medical-information/phase-i-results-of-venetoclax-combined-with-azacytidine-in-high-risk-mds-or-cmml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-new-treatments-are-available-for-high-risk-mds-what-does-this-mean-for-patients monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/visual-abstract-azacitidine-lenalidomide-and-dli-as-salvage-therapy-for-mds-cmml-and-saml-after-allo-hsct-azalena monthly 0.9 2022-10-28T16:05:00.000Z https://mds-hub.com/medical-information/safety-and-efficacy-of-enasidenib-in-idh2-mutated-myelodysplastic-syndrome monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-do-the-panther-trial-results-tell-us-about-first-line-treatment-for-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-successful-is-cpx-351-as-first-line-treatment-for-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/hla-mis-matching-in-haploidentical-transplantation monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/efficacy-and-safety-of-eprenetapopt-apr-246-combined-with-azacitidine-in-patients-with-tp53-mutant-mds-and-oligoblastic-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/clinico-biological-features-and-prognosis-of-patients-with-mdsmpn-u-with-isolated-isochromosome-17q monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/a-personalized-prognostic-prediction-model-based-on-genomic-features-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-new-developments-are-there-in-the-treatment-of-relapsed-or-refractory-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/visual-abstract-roxadustat-for-the-treatment-of-anemia-in-patients-with-lower-risk-myelodysplastic-syndrome-open-label-dose-selection-lead-in-stage-of-a-phase-3-study monthly 0.9 2022-10-28T16:05:00.000Z https://mds-hub.com/medical-information/the-ipss-molecular-a-new-risk-stratification-for-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/ash21-abstracts-what-s-hot-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/should-novel-agents-be-used-prior-to-transplant-in-mds-eb12 monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/fda-approval-given-for-injectable-form-of-decitabine monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-efficacy-and-safety-of-ofatumumab-plus-prednisone-in-cgvhd monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/venetoclax-with-intensive-chemotherapy-for-younger-patients-with-nd-aml-or-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-we-predict-drug-resistance-in-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/fludarabinetreosulfan-for-allo-hct-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/post-transplant-maintenance-therapy-low-dose-decitabine-venetoclax-is-safe-and-effective-for-high-risk-aml-and-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/geriatric-hematology-in-low-resource-settings-improving-care-for-older-people-through-the-implementation-of-geriatric-hematology-programs monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/a-generic-version-of-lenalidomide-capsules-has-been-approved-by-the-fda-for-mds-and-mm monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-eha-research-roadmap-updates-for-malignant-myeloid-disorders monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/impact-of-type-of-blood-cancer-on-the-outcome-following-stem-cell-transplantation monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/fludarabine-melphalan-vs-fludarabine-busulfan-effects-on-transplantation-outcomes-in-older-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-treatment-would-you-suggest-for-high-risk-mds-patients-not-fit-for-chemotherapy-or-hsct monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-the-priority-challenges-in-mds-treatment monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-have-oral-hypomethylating-agents-changed-the-management-of-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/personalized-prediction-model-for-risk-stratification-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/safety-and-effectiveness-of-dec-plus-ven-as-a-maintenance-therapy-in-patients-with-high-risk-aml-and-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/editorial-theme-or-novel-targeted-agents-for-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/allogeneic-stem-cell-transplantation-vs-5-azacytidine-treatment-in-elderly-patients-with-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/improvement-in-qol-post-red-cell-transfusion-and-feasibility-of-peri-transfusion-qol-assessment-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/epicovideha-registry-epidemiology-and-outcomes-in-patients-with-hematologic-malignancies-infected-with-covid-19 monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/double-minute-chromosomes-associated-with-rare-cytogenetic-abnormalities-and-poor-prognosis-in-mds-and-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/sabatolimab-for-the-treatment-of-poor-prognosis-myelodysplastic-syndromes-and-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/rvu120-a-cdk8-inhibitor-for-the-treatment-of-anemia-in-mds-and-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/fda-has-granted-breakthrough-therapy-designation-to-venetoclax-in-combination-with-azacitidine-for-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/eha2021-practice-changing-abstracts-in-myelodysplastic-syndromes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-the-hematologic-toxicities-with-ven-aza-be-managed-more-effectively monthly 0.9 2021-07-12T15:24:00.000Z https://mds-hub.com/medical-information/hot-off-the-press-or-understanding-patient-s-burden-quality-of-life-and-alignment-of-patient-reported-outcome-measures-to-capture-changes-in-high-risk-mdsaml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/prevalence-and-impact-of-ppm1d-mutations-in-patients-with-mds-and-del-5q monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-hematologic-toxicities-occur-after-venetoclax-and-azacitidine-in-mds-and-how-can-they-be-managed monthly 0.9 2021-06-30T10:38:00.000Z https://mds-hub.com/medical-information/what-hematologic-toxicities-occur-after-venetoclax-azacitidine-in-mds-and-how-can-they-be-managed monthly 0.9 2021-06-24T16:22:00.000Z https://mds-hub.com/medical-information/iron-overload-screening-treatment-modalities-and-therapies-in-pediatric-post-hsct-patients monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/highlights-of-eha-2021 monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/will-luspatercept-become-the-new-treatment-standard-after-esa-failure-in-rs-positive-lr-mds-patients-with-td-anemia monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-use-of-whole-genome-sequencing-as-an-alternative-diagnostic-tool-for-cytogenetic-analysis-in-myeloid-cancers monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-baseline-factors-affect-qol-in-mds-how-do-these-change-with-treatment monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/which-subgroups-of-patients-benefit-most-from-a-ven-aza-combination monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/ccus-with-dysplasia-a-clinically-relevant-precursor-to-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/initiation-of-a-phase-ii-trial-of-lemzoparlimab-combined-with-azacitidine-to-treat-amlmds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/initiation-of-the-first-in-human-trial-of-fhd-286-a-first-in-class-dual-inhibitor-to-treat-rr-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/novel-targeted-therapies-post-hsct-for-amlmds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/efficacy-and-safety-of-cc-486-oral-azacitidine-in-patients-with-lower-risk-myelodysplastic-syndromes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/allo-hsct-in-patients-with-therapy-related-aml-or-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/prognosis-and-treatment-for-pediatric-patients-who-relapse-following-first-allo-hsct monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/interim-but-promising-updates-on-first-in-human-phase-iii-clinical-trial-for-gtb-3550-triketm-to-treat-rr-mdsaml-patients monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/oral-formulations-of-cedazuridine-and-decitabine-for-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-should-molecular-profiling-be-used-to-guide-mds-therapy monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/ca-4948-an-irak4-inhibitor-attained-orphan-drug-designation-by-the-fda-for-the-treatment-of-relapsedrefractory-mds-and-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/germline-mutations-in-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/progress-in-immunotherapy-for-hematologic-malignancies monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/drss-a-new-disease-risk-stratification-system-for-hematologic-malignancies monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/augmented-reduced-intensity-allo-hsct-in-patients-with-high-risk-aml-or-mds-results-of-the-figaro-trial monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/early-italian-experience-of-covid-19-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-immunotherapy-be-used-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/maintenance-therapy-after-allo-hsct-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-the-new-approaches-for-anemia-treatment-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/initiation-of-the-first-in-human-trial-of-allogeneic-nkg2d-directed-car-nk-cell-therapy-to-treat-rr-aml-or-high-risk-rr-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/editorial-theme-or-immune-dysregulation-and-genetic-mutations-associated-with-mds-pathogenesis monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/is-car-t-an-option-for-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/eprenetapopt-with-azacitidine-for-tp53-mutant-mdsaml-results-from-two-ongoing-clinical-trials monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-is-new-for-mds-with-del-5q monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/initiation-of-a-phase-i-trial-of-sp-420-a-new-iron-chelator-for-transfusion-dependent-patients-with-mds-and-mf monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/outcomes-of-patients-with-cmml-treated-with-hypomethylating-agents monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-does-covid-19-infection-affect-hematopoiesis-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/lenalidomide-and-epoetin-alfa-for-the-treatment-of-patients-with-low-risk-non-del-5q-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/updated-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up-of-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/jsp191-conditioning-for-patients-with-aml-or-mds-preliminary-results-from-a-phase-i-clinical-trial monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-novel-strategies-to-treat-low-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-we-tailor-treatment-to-improve-outcome-in-mds-2 monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-mutational-landscape-in-patients-with-mdscmml-and-systemic-inflammatory-and-autoimmune-diseases monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/is-there-a-place-for-immunotherapy-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-novel-strategies-to-treat-higher-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-novel-therapeutic-approaches-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-should-we-manage-hma-failure monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/targeted-sequencing-of-seven-genes-may-improve-classification-of-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/meta-analysis-and-retrospective-pharmacovigilance-study-of-mds-and-aml-in-patients-receiving-parp-inhibitor-treatment monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-is-new-for-treating-patients-with-low-risk-mds monthly 0.9 2021-01-29T21:05:00.000Z https://mds-hub.com/medical-information/imetelstat-for-patients-with-highly-transfusion-dependent-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/phase-iii-dacota-trial-will-hydroxyurea-remain-soc-for-advanced-proliferative-cmml monthly 0.9 2025-02-10T13:31:00.000Z https://mds-hub.com/medical-information/editorial-theme-or-genetic-pathogenesis-of-mds-translating-molecular-advances-into-better-diagnosis-and-prognosis-of-ccus-and-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/lenalidomide-reduces-risk-of-transfusion-dependency-in-lower-risk-mds-interim-results-of-the-sintra-rev-trial monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-we-tailor-treatment-to-improve-outcome-in-mds monthly 0.9 2021-01-29T20:44:00.000Z https://mds-hub.com/medical-information/can-changes-in-dna-methylation-pattern-predict-the-response-to-hma-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/real-world-data-on-mds-with-ring-sideroblasts-after-esa-failure monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-we-improve-on-current-risk-stratification-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/results-from-the-phase-ii-p-2001-study-on-pevonedistat-plus-azacytidine-for-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-is-the-clinical-impact-of-ddx41-mutations-in-myeloid-neoplasms monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/should-the-telomerase-inhibitor-imetelstat-become-soc-in-transfusion-dependent-low-risk-mds monthly 0.9 2024-06-25T15:44:00.000Z https://mds-hub.com/medical-information/eprenetapopt-with-azacytidine-did-not-significantly-improve-cr-rates-in-tp53-mutated-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/ric-allo-sct-vs-hma-or-best-supportive-care-in-older-patients-with-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/phase-ib-cimon-trial-of-maat033-receives-positive-first-dsmb-safety-review-in-patients-with-aml-and-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/tp53-allelic-state-has-implications-in-mds-in-terms-of-genomic-stability-clinical-presentation-and-outcomes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/why-is-tim3-a-good-target-for-treating-patients-with-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/phase-i-study-ca-4948-monotherapy-in-rr-mds-shows-positive-preliminary-results monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/p-2001-study-which-patients-benefit-most-from-pevonedistat-plus-azacitidine monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/when-should-we-consider-allo-sct-for-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/azacitidine-maintenance-after-hsct-for-amlmds-provides-no-improvement-in-relapse-free-survival-in-phase-iii-study monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/tosedostat-a-potential-treatment-option-for-mds-after-hypomethylating-agent-failure monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-the-challenges-in-diagnosing-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/practice-changing-abstracts-at-eha-2020 monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/how-can-cytogenetics-predict-response-to-venetoclax-and-azacitidine-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/decitabine-plus-cedazuridine-approved-by-the-fda-for-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/characterizing-the-genetic-landscape-of-patients-with-myelodysplasticmyeloproliferative-neoplasms monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/outcomes-of-hsct-in-blast-phase-of-bcr-abl1-negative-mpn-compared-with-de-novo-and-post-mds-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/targeted-therapeutics-in-mds-what-s-the-current-state-of-play monthly 0.9 2020-12-03T10:24:00.000Z https://mds-hub.com/medical-information/updates-from-ncri-aml18-and-aml-19-trials monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/oral-cedazuridinedecitabine-offers-comparable-efficacy-and-safety-to-iv-decitabine-in-mds-and-cmml-with-enhanced-qol-opportunities monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/regenerative-medicine-advanced-therapy-and-orphan-drug-designation-given-to-orca-t monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/inherited-hematologic-malignancies-predisposition-syndromes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/fda-grants-apg-115-orphan-drug-designation-for-the-treatment-of-aml-and-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-spectrum-of-clonal-hematopoiesis monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/a-matter-of-size-telomere-length-predicts-survival-before-allo-sct-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-the-challenges-in-assessing-response-to-treatment-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-are-the-new-approaches-for-anemia-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-is-the-relationship-between-the-sf3b1-splicing-mutation-and-therapy-related-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-challenge-of-diagnosing-low-grade-myelodysplastic-syndromes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/therapy-related-mds-deserve-specific-diagnostic-sub-classification-and-risk-stratificationan-approach-to-classification-of-patients-with-t-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/magrolimab-gets-fda-breakthrough-therapy-designation-for-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/residual-circulating-tumor-dna-as-a-prognostic-biomarker-in-patients-with-amlmds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-real-world-experience-of-venetoclax-and-hypomethylating-agent-therapy-in-high-risk-myelodysplastic-syndromes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/non-myeloablative-allo-hsct-for-patients-with-hematological-malignancies-a-20-year-summary-of-clinical-changes monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/apr-246-plus-azacitidine-for-patients-with-tp53-mutated-mds-and-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/is-there-synergy-between-anti-tim-3-therapy-and-hmas-in-the-treatment-of-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-is-the-benefit-of-adding-pevonedistat-to-azacitidine-in-patients-with-high-risk-mds-or-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/what-does-the-stimulus-program-tell-us-about-combination-therapy-with-mbg453-in-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/is-azacitidine-apr-246-safe-and-effective-in-tp53-mutated-mds-and-aml monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/does-imetelstat-provide-transfusion-independence-in-lower-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/magrolimab-plus-azacytidine-in-patients-with-myelodysplastic-syndromes-and-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/luspatercept-approved-for-transfusion-dependent-anemia-in-patients-with-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/can-cd47-antibody-therapy-be-safely-used-for-aml-and-mds monthly 0.9 2020-12-03T10:25:00.000Z https://mds-hub.com/medical-information/the-role-of-the-nlrp3-inflammasome-in-hematological-pathologies monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/the-impact-of-cd33-and-abcb1-snps-on-clinical-outcomes-in-aml-a-retrospective-analysis-of-a-phase-ii-decitabine-and-gemtuzumab-ozogamicin-study-in-aml-and-high-risk-mds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/outcomes-of-long-term-survivors-after-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/medical-information/post-transplant-cyclophosphamide-for-the-management-of-gvhd-in-patients-receiving-immune-checkpoint-inhibitors-for-amlmds monthly 0.9 2022-07-04T12:55:00.000Z https://mds-hub.com/about-us/louise-niven monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/helen-croxall-1 monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/jen-wilkinson monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/abhilasha-verma monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/megan-kelly monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/haimanti-mandal monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/quintina-dawson monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/dylan-barrett monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/sabina-ray monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/beth-campbell monthly 0.6 2026-02-25T14:59:00.000Z https://mds-hub.com/about-us/ella-dixon monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/oscar-williams monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/jennifer-higgins monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/kreena-mistry monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/becky-lowe monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/mark-maitland monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/amy-mensah monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/jessica-silva monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/natasha-fort monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/danielle-ferrie monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/molly-tracy monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/erika-roa monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/lottie-hutton monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/lauren-lett monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/jack-ladhams monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/about-us/abbie-mckillop monthly 0.6 2024-11-12T12:33:00.000Z https://mds-hub.com/contributors/theo-de-witte monthly 0.6 2023-12-12T16:40:00.000Z https://mds-hub.com/contributors/yasushi-miyazaki monthly 0.6 2023-12-14T10:30:00.000Z https://mds-hub.com/contributors/uwe-platzbecker monthly 0.6 2024-06-25T15:44:00.000Z https://mds-hub.com/contributors/rena-buckstein monthly 0.6 2023-10-24T10:26:00.000Z https://mds-hub.com/contributors/pierre-fenaux monthly 0.6 2023-12-12T16:40:00.000Z https://mds-hub.com/contributors/mikkael-a-sekeres monthly 0.6 2023-10-24T10:26:00.000Z https://mds-hub.com/contributors/guillermo-garcia-manero monthly 0.6 2023-10-24T10:26:00.000Z https://mds-hub.com/contributors/eva-hellstrom-lindberg monthly 0.6 2023-10-24T10:26:00.000Z https://mds-hub.com/contributors/rafael-bejar monthly 0.6 2023-12-12T16:40:00.000Z https://mds-hub.com/contributors/alex-smith monthly 0.6 2023-10-24T10:26:00.000Z https://mds-hub.com/contributors/moshe-mittelman monthly 0.6 2023-10-24T10:26:00.000Z https://mds-hub.com/steering-committees monthly 0.7 2026-04-03T18:49:35.979Z https://mds-hub.com/about-us monthly 0.7 2026-04-03T18:49:35.979Z https://mds-hub.com/newsletter monthly 0.7 2026-04-03T18:49:35.979Z https://mds-hub.com/our-hubs monthly 0.7 2026-04-03T18:49:35.979Z https://mds-hub.com/contact monthly 0.7 2026-04-03T18:49:35.979Z